Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
Launched by NOVARTIS PHARMACEUTICALS · Dec 12, 2024
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Patients who initiated OMB commercially from the time of disease modifying therapy (DMT) approval (August 2020), and
- • Aged 18 years or older at index date, and
- • Patients who met 2017 McDonald Criteria for clinically definite multiple sclerosis (MS), or
- • Patients diagnosed with clinically isolated syndrome (CIS) by Cleveland Clinic MS specialist.
- • Exclusion criteria: Those who were participating in OMB clinical trials (e.g., ARTIOS, OLIKOS)
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
East Hanover, New Jersey, United States
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported